February 09, 2026

Managing Idiopathic Acute Pancreatitis

Expert panel weighs evidence for genetic testing, cholecystectomy, and ERCP in patients with unexplained acute pancreatitis amid limited guideline direction.

Conexiant

January 28, 2026

Nivolumab Added to Chemoradiotherapy Reduced Recurrence Risk in High-Risk Head and Neck Cancer

Adding the PD-1 inhibitor nivolumab to standard chemoradiotherapy after surgery significantly reduced recurrence rates for patients with locally advanced head and neck squamous cell carcinoma who are ...

The ASCO Post

January 27, 2026

Addition of Xevinapant to Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck

In a phase III trial (TrilynX) reported in the Journal of Clinical Oncology, Bourhis et al found that the addition of xevinapant (an inhibitor of apoptosis proteins inhibitor) to platinum-based chemor...

The ASCO Post

January 27, 2026

10-Year Incidence of Second Cancers in HPV-Positive Oropharyngeal Cancer

At 10 years, the cumulative incidence of radiation-induced second malignancies in patients receiving definitive radiation therapy for oropharyngeal cancers associated with human papillomavirus (HPV) w...

The ASCO Post

January 07, 2026

Hybrid AI Approach With Uncertainty Quantification for Mammography Reading Supports Safe Workload Reduction

Investigators have developed and tested a hybrid reading strategy for screening mammography images with artificial intelligence (AI) that includes reads from radiologists and a stand-alone AI interpre...

The ASCO Post

January 02, 2026

Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC

The expanded indication marks the first and only radioembolization therapy in the United States approved to treat both unresectable hepatocellular carcinoma (HCC) and colorectal cancer liver metastase...

The ASCO Post

January 02, 2026

Benefits Mount for TROP2-Directed Antibody-Drug Conjugates in Triple-Negative Breast Cancer

Two randomized phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2025 bolster support for the use of antibody–drug conjugates—in particular, trophoblast cell surf...

The ASCO Post

December 18, 2025

Can Prophylactic Radiation Prevent Complications of Bone Metastases in High-Risk, Asymptomatic Patients?

Some bone metastases appear to be at higher risk for such complications as pathologic fracture, spinal cord compression, pain or surgery to bone, even if they’re asymptomatic

Roswell Park Comprehensive Cancer Center

December 15, 2025

Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers

Rates of local regional recurrence were very low for patients with early-stage triple-negative or HER2-positive breast cancer regardless of whether or not they received a breast MRI for staging and su...

The ASCO Post